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Abstract 
Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising 
from mesenchymal cells of the submesothelial tissue. We present here the case of a patient 
diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura 
whose disease failed to respond to combination cytotoxic chemotherapy agents, but demon-
strated a prompt near-complete response to checkpoint blockade treatment using the anti-
programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular 
profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-
L1) and PD-1. The patient experienced minimal adverse effects from the treatment with du-
rable favorable response lasting up to cycle 26. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
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Solitary fibrous tumor of the pleura (SFTP) is a rare primary neoplasm that arises from 
mesenchymal cells of the areolar tissue in the submesothelial layer of the pleura. It accounts 
for less than 5% of primary pleural neoplasms [1]. The neoplasm is usually benign, with 
reported malignancy accounting for up to 20% of cases. Surgical resection of SFTP usually 
yields a favorable outcome with a 5-year disease-free survival rate of 81% [2]. However, 
malignant SFTP has a 63% recurrence rate even following curative-intent complete surgical 
resection [3]. Due to the rarity of malignant SFTP, there is a striking lack of published litera-
ture on the efficacy of specific therapeutic regimens. Much focus has recently been directed 
by the clinical oncology community towards immune system-modulating therapies, includ-
ing immune checkpoint blockade therapy [4]. One such approach involves administration of 
monoclonal antibodies with binding specificity to the programmed cell death protein 1 (PD-
1) expressed on the surface of T cells or the programmed death-ligand 1 (PD-L1) expressed 
on the surface of tumor cells [5, 6]. 
PD-L1 on healthy human cells binds to T-cell PD-1, initiating an inhibitory signaling cas-
cade that has the effect of preventing development of a cytotoxic T-cell attack against the 
cells. We present the case of a patient with malignant SFTP whose disease failed to respond 
to several combination chemotherapy regimens but eventually demonstrated a durable 
near-complete response to checkpoint immunotherapy in the form of the anti-PD-1 mono-
clonal antibody pembrolizumab. 
Case Report 
A 50-year-old Caucasian male with a 30 pack-year smoking history, who was healthy 
with the only known medical issue being controlled hypertension, presented to the clinic 
with a sore lump over the right lower chest wall between the 6th and 7th ribs. Initial workup 
with CT chest imaging in December 2014 revealed a soft tissue mass arising within the right 
chest wall underlying the palpable lump. A follow-up CT of the chest, abdomen, and pelvis in 
January 2015 confirmed an enlarging underlying soft tissue mass arising within the chest 
wall soft tissue/pleural tissue space, centered over the intercostal space, measuring 3.0 × 5.9 
× 5.0 cm. An enlarged right mid-hilar lymph node superior to the right pulmonary artery 
measuring 2.7 × 3.1 × 2.7 cm was seen as well. Ultrasound-guided needle biopsy was per-
formed on the chest wall mass, and subsequent pathological analysis, including a pathology 
review at the Mayo Clinic, revealed an extensively necrotic, poorly differentiated malignant 
neoplasm possibly representing a malignant SFTP (Fig. 1a). Immunohistochemistry analysis 
revealed that the neoplastic cells were diffusely positive for CD34 (Fig. 1b) and focally wide-
spectrum cytokeratin-positive. INI-1 expression was retained. WT-1, calretinin, ER, CD31, 
ERG protein, FLI-1, and high MW cytokeratin were negative. PET/CT imaging in February 
2015 showed no evidence of metastatic lesions in the abdomen, pelvis, or bones, and a bone 
scan was also negative for any distant metastases. The right lower chest wall mass was 
found intensely hypermetabolic with SUVmax 23, with the right hilar mass having SUVmax 
20 (Fig. 2a–d). 
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The patient received front-line definitive concurrent chemoradiation treatment at a lo-
cal cancer center using low-dose weekly carboplatin and paclitaxel and daily radiotherapy to 
a total dose of 64 Gy. Restaging by PET/CT showed shrinkage of the primary chest wall mass 
to 2.8 × 1.4 cm and persistence of the right hilar nodal mass. However, new soft tissue foci 
with FDG hypermetabolism were seen in the deep subcutaneous tissue of the left posterior 
abdominal wall at the level of the transverse process of the third vertebra, as well as two 
nodular foci at the pleural thickening of the right lung apex. Further consideration of surgical 
resection was canceled. Punch biopsy of the new subcutaneous mass revealed pathological 
characteristics similar to the previous biopsy, confirming metastatic dissemination. Based on 
this finding, a second-line palliative chemotherapy regimen of gemcitabine and docetaxel 
was initiated. However, after the first cycle of treatment, the patient suffered severe life-
threatening treatment-related toxicities, including neutropenic fever, pneumonia, severe 
fatigue, mouth sores, oral candidiasis, nausea/vomiting, decreased oral intake, and prerenal 
acute renal failure secondary to dehydration, requiring hospitalization. The chemotherapy 
regimen was aborted after successful treatment with antimicrobials and rehydration thera-
py in the hospital. The patient sought second opinion from a tertiary cancer institute, and 
was started on the MD Anderson regimen, which has reported efficacy for malignant SFTP in 
the literature, using temozolomide and bevacizumab (temozolomide 150 mg/m2 orally on 
days 1–7 and days 15–21, plus bevacizumab 5 mg/kg i.v. on days 8 and 22, repeated every 
28-day cycle) [7]. However, after three cycles of this combination regimen, PET imaging in 
October 2015 showed further progression of the disease (Fig. 2e). 
Genomic profiling analysis of the primary tumor using the FoundationHeme® assay re-
vealed possible amplification of EGFR (equivocal), CDKN2A p16INK4a-R112P, TP53-V157F, 
CPS1-L878fs*8, and SMARCA4-E1364*. Since no definitive actionable genomic alterations 
were evident, we sought comprehensive multi-platform molecular and genomic profiling 
with the Caris Molecular Intelligence® (CMI-X) test (Table 1) while the patient was undergo-
ing temozolomide plus bevacizumab therapy. CMI-X tumor profiling confirmed positive re-
sults for PD-1 and PD-L1 (2+, 5%; Fig. 1c) in immunohistochemistry assays. Te-
mozolomide/bevacizumab treatment was eventually found ineffective soon thereafter. 
Notably, the CMI-X molecular profiling also suggested potential lack of benefit to te-
mozolomide therapy based on being MGMT-positive via IHC (1+, 45%; Table 1). The key 
genomic alterations found in the next-generation sequencing (NGS) test include: TP53-
V157F (56%), CDKN2A-R112P (62%), and MLH1-E234Q (52%). Altogether, these above 
findings prompted us to switch treatment strategy and ultimately we initiated treatment 
with an anti-PD-1 immune checkpoint monoclonal antibody in October 2015; pembroli-
zumab was selected for off-label use, using the FDA-approved dose regimen of 2 mg/kg in-
travenously every 3 weeks. When the patient returned for tumor response assessment in 
December 2015 after 2 cycles of treatment, he reported excellent tolerance and notable dim-
inution of the left abdominal wall mass, which was confirmed as a prompt partial response 
by CT scan imaging (Fig. 2e). Restaging scan via CT imaging after the 5th cycle of pembroli-
zumab confirmed a near-complete response in February 2016. Prior to the planned 13th 
course of therapy, the patient reported no palpable masses, and restaging via CT scan imag-
ing in July 2016 confirmed an ongoing persistent near-complete response with no new dis-
ease recurrence (Fig. 2e). To date, the patient has durable near-complete response after up 
to a total of 26 cycles of pembrolizumab infusions, and he remains well with excellent toler-
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ance without significant adverse effects except for mild dry skin. The patient reported pro-
gressively improved energy throughout therapy, and his family reported that he regained his 
appetite and his ability to complete all tasks of daily living. He was found to have a new soli-
tary left apical PET-avid pleural based mass biopsy-proven to be of similar histologic diagno-
sis as PD-1 therapy-acquired resistant disease after cycle 26. He received local radiotherapy 
to the isolated pembrolizumab-resistant tumor mass and continuation PD-1 immunotherapy 
with resultant ongoing response after cycle 31. 
Discussion 
Our case report highlights the substantial potential of PD-1/PD-L1 checkpoint pathway 
blockade in cancer immunotherapy. To date, the anti-PD-1 checkpoint antibodies nivolumab 
and pembrolizumab have been FDA-approved for the treatment of previously treated ad-
vanced melanoma and non-small cell lung cancer (NSCLC) [8–10]. Expansion of its use is 
evident in the growing list of tumor types that show treatment response with such treatment 
strategy, including classic Hodgkin lymphoma [11] and head and neck cancer [12]. While the 
role of PD-L1 tumoral expression as a predictive biomarker for anti-PD-1 immunotherapy 
remains to be better refined, it has been approved as a companion diagnostic in the pem-
brolizumab approval by the FDA. Pembrolizumab has also recently been approved as first-
line therapy in advanced NSCLC patients whose tumor has strong PD-L1 expression as de-
fined by tumor proportion score (TPS) ≥50%, based on the positive survival data from the 
phase III KEYNOTE-024 study of single-agent pembrolizumab versus standard-of-care plati-
num-based doublet chemotherapy [13]. In May 2017, pembrolizumab received additional 
FDA approval as a first-line checkpoint inhibitor in combination with carboplatin and 
pemetrexed in advanced non-squamous NSCLC regardless of PD-L1 status [14]. A cancer 
type such as malignant SFTP is so rare that it is unrealistic to expect completion of phase III 
clinical studies to validate the treatment efficacy of immune checkpoint therapies. Thus, it is 
of practical value to observe and report remarkable responders in N = 1 study or case re-
ports. Our case study also illustrates that even with a low level of detected PD-L1 expression 
status of TPS 5%, a prompt and ultimately durable remarkable near-complete response in 
chemotherapy- and radiation-refractory disease is possible. To our knowledge, this is the 
first report of a treatment response of a malignant SFTP to cancer checkpoint immunothera-
py. Our PD-1 blockade strategy success serves as a reminder that the new paradigm of can-
cer immunotherapy can unleash significant anti-tumor effects even in heavily pretreated or 
chemotherapy- and radiation-refractory tumors. Moreover, other immune checkpoint inhibi-
tors such as PD-L1 antibodies (e.g., atezolizumab, durvalumab/MEDI4736) or immune-
modulating agents such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTL4) antibod-
ies (e.g., tremelimumab, ipilimumab) would also merit further studies to determine their 
potential efficacy in orphan diseases like SFTP. Further research in cancer immunotherapy 
predictive biomarkers is urgently necessary for optimizing patient selection for treatment. 
Undoubtedly, cancer immunotherapy has revolutionized modern cancer treatment and will 
continue to make further strides in improving cancer patients’ treatment outcomes in future 
years. 
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Fig. 1. Histopathologic features of the malignant solitary fibrous tumor of the pleura (SFTP). a A low-
powered view of hematoxylin and eosin staining, demonstrating the hypercellularity of the tumor (mag. 
100×) with the high-powered view demonstrating numerous mitoses shown in the inset (mag. 400×).  
b A high-powered view demonstrating positive immunohistochemical staining for CD34 expression of the 
SFTP (mag. 400×). c A low-powered view demonstrating positive immunohistochemical staining for PD-L1 
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Fig. 2. Positron-emission tomography (PET)/computed tomography (CT) scan imaging of the patient with 
malignant solitary fibrous tumor of the pleura (SFTP) at the time of initial diagnosis and during PD-1 
checkpoint inhibition response. Shown here are the selected sites of disease (yellow arrows) in the right 
hilar mass (a, b) and in the right lower chest wall mass (c, d) at the time of initial diagnosis. e Tumor re-
sponse of the refractory malignant SFTP in the left posterior abdominal wall mass to PD-1-targeting 
checkpoint immunotherapy using pembrolizumab. Serial imaging in the pulmonary hilar region (top pan-
els) and in the lower abdominal region (lower panels) during the course of treatment with pembrolizumab 
are shown here for illustration. Yellow arrows, pretreatment tumor burden; red arrow, early tumor re-
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Table 1. Comprehensive molecular tumor profiling with Caris Molecular Intelligence (CMI)-X assay 
   
   
Molecular-genomic alterations Therapy options with 
potential benefits 
Therapy options with 
potential lack of benefits 
   
   
TP53 exon 5 | V157F (56%) n/a n/a 
      CDKN2A exon 2 | R112P (62%) n/a n/a 
      MLH1 exon 9 | E234Q (52%) n/a n/a 
      PTEN IHC – positive n/a n/a 
      TS IHC – positive (1+ 75%) n/a Capecitabine, fluorouracil, 
pemetrexed 
      TOPO1 IHC – positive (2+ 35%) Irinotecan, topotecan n/a 
      TOP2A IHC – positive (2+ 30%) Doxorubicin, epirubicin, liposomal doxoru-
bicin 
n/a 
      TUBB3 IHC – positive (2+ 85%) n/a n/a 
      TLE3 IHC – positive (2+ 30%) Docetaxel, nab-paclitaxel, paclitaxel n/a 
      PGP IHC – negative Docetaxel, nab-paclitaxel, paclitaxel, doxo-
rubicin, epirubicin, liposomal  
doxorubicin 
n/a 
      ERCC1 IHC – negative Carboplatin, cisplatin, oxaliplatin n/a 
      MGMT IHC – positive (1+ 45%)  Dacabazine, temozolomide 
      PD-L1 IHC positive (2+ 5%) Nivolumab, pembrolizumab n/a 
      PD-1 IHC – positive (1/HPF) Nivolumab, pembrolizumab n/a 
   
   
 
 
 
